
(12) SOLICITUD INTERNACIONAL PUBLICADA EN VIRTUD DEL TRATADO DE COOPERACIÓN EN MATERIA DE PATENTES (PCT)

(19) Organización Mundial de la Propiedad Intelectual

Oficina internacional





(10) Número de Publicación Internacional WO 2013/150167 A3

- (51) Clasificación Internacional de Patentes: *C12Q 1/68* (2006.01)
- (21) Número de la solicitud internacional:

PCT/ES2013/070218

(22) Fecha de presentación internacional:

3 de abril de 2013 (03.04.2013)

(25) Idioma de presentación:

español

(26) Idioma de publicación:

español

(30) Datos relativos a la prioridad: P201230513 3 de abril de 2012 (03.04.2012) ES

(71) Solicitantes: SERVICIO ANDALUZ DE SALUD [ES/ES]; Avda. De La Constitución,18, Sevilla, E-41071 Sevilla (ES). UNIVERSIDAD DE SEVILLA [ES/ES]; Pabellón de Brasil, Pº de las Delicias, s/n, Sevilla, E-41013 Sevilla (ES). CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS [ES/ES]; Avda de María Luisa, s/n, Palacio Pabellón de Perú, Sevilla, E-41013 Sevilla (ES).

(72) Inventores; e


(71) Solicitantes (para US solamente): GARCÍA CARBONERO, Rocío [ES/ES]; Fundación Pública Andaluza Progreso Y Salud, Avda. Américo Vespucio 5, Bloque 2, 2°, Planta Izq., Parque Científico y Tecnológico

Cartuja 93 Sevilla E-41092 Sevilla (ES). PAZ-ARES, Luis Gonzalo [ES/ES]; Fundación Pública Andaluza Progreso Y Salud, Avda. Américo Vespucio 5, Bloque 2, 2º, Planta Izq., Parque Científico y Tecnológico Cartuja 93 Sevilla E-41092 Sevilla (ES). MOLINA PINELO, Sonia [ES/ES]; Fundación Pública Andaluza Progreso Y Salud, Avda. Américo Vespucio 5, Bloque 2, 2º, Planta Izq., Parque Científico y Tecnológico Cartuja 93 Sevilla E-41092 Sevilla (ES). CARNERO MOYA, Amancio [ES/ES]; Fundación Pública Andaluza Progreso Y Salud, Avda. Américo Vespucio 5, Bloque 2, 2º, Planta Izq., Parque Científico y Tecnológico Cartuja 93 Sevilla E-41092 Sevilla (ES). SUAREZ BELTRAN, Rocio [ES/ES]; Fundación Pública Andaluza Progreso Y Salud, Avda. Américo Vespucio 5, Bloque 2, 2º, Planta Izq., Parque Científico y Tecnológico Cartuja 93 Sevilla E-41092 Sevilla (ES).

- (74) Mandatario: FÚSTER OLAGUIBEL, Gustavo; C/ Paseo de la Habana 9-11, Madrid, E-28036 Madrid (ES).
- (81) Estados designados (a menos que se indique otra cosa, para toda clase de protección nacional admisible): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,

[Continúa en la página siguiente]

- (54) Title: MICRO-RNA EXPRESSION MODEL AS AN INDICATOR OF SURVIVAL OF PATIENTS AFFECTED BY METASTATIC COLORECTAL CANCER
- **(54) Título**: MICRO-RNA EXPRESSION MODEL AS AN INDICATOR OF SURVIVAL OF PATIENTS AFFECTED BY METASTATIC COLORECTAL CANCER



- (57) Abstract: Colorectal cancer is among the most common causes of cancer-related death in the Western world and one of the most common malignant tumours in the world. Treatment for metastatic colorectal cancer normally includes chemotherapy, although success rates vary considerably among patients. It is therefore necessary to predict responses and survival rates in individual patients. The present invention provides methods and tools that represent greater progress. In particular, the invention provides information on a set of microRNAs which can be used in methods for predicting the survival of patients treated with chemotherapy. The invention also relates to the tools which can be used in said prediction methods.
- (57) Resumen: El cáncer colorrectal está entre las causas más comunes de muerte relacionada con cáncer en el mundo occidental y entre los tumores malignos más comunes en el mundo. El tratamiento del cáncer colorrectal metastásico comprende normalmente quimioterapia, aunque el éxito de la terapia varía significativamente entre los pacientes. Existe de esta manera una necesidad de predecir la respuesta y las índices de supervivencia de los pacientes individuales. La presente invención proporciona procedimientos

[Continúa en la página siguiente]

- KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, Publicada: LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Estados designados (a menos que se indique otra cosa, para toda clase de protección regional admisible): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), euroasiática (AM, AZ, BY, KG, KZ, RU, TJ, TM), europea (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- con informe de búsqueda internacional (Art. 21(3))
- antes de la expiración del plazo para modificar las reivindicaciones y para ser republicada si se reciben modificaciones (Regla 48.2(h))
- con la parte de lista de secuencias de la descripción (Regla 5.2(a))
- (88)Fecha de publicación del informe de búsqueda internacional:

30 de enero de 2014

Solicitud internacional Nº

PCT/ ES2013/070218

A. CLASIFICACIÓN DEL OBJETO DE LA SOLICITUD INV. C12Q1/68

De acuerdo con la Clasificación Internacional de Patentes (CIP) o según la clasificación nacional y CIP.

B. SECTORES COMPRENDIDOS POR LA BÚSQUEDA

Documentación mínima buscada (sistema de clasificación seguido de los símbolos de clasificación)

C12Q

Otra documentación consultada, además de la documentación mínima, en la medida en que tales documentos formen parte de los sectores comprendidos por la búsqueda

Bases de datos electrónicas consultadas durante la búsqueda internacional (nombre de la base de datos y, si es posible, términos de búsqueda utilizados)

EPO-Internal, BIOSIS, EMBASE, FSTA, WPI Data

C. DOCUMENTOS CONSIDERADOS RELEVANTES

| Categoría* | Documentos citados, con indicación, si procede, de las partes relevantes | Relevante para las reivindicaciones Nº |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| X | N Knijn: "Current Issues in the Targeted Therapy of Advanced Colorectal Cancer", Discovery Medicine, 10 Abril 2010 (2010-04-10), XP055080024, Encontrado en Internet: URL:http://www.discoverymedicine.com/Nikki-Knijn/2010/04/10/current-issues-in-the-targeted-therapy-of-advanced-colorectal-cancer/[encontrado en 2013-09-19] resumen párrafo [introducción] tablas 1, 2a | 18,19 |

| En la continuación del Recuadro C se relacionan otros documentos | Los documentos de familias de patentes se indican en el Anexo | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| * Categorías especiales de documentos citados: "A" documento que define el estado general de la técnica no considerado como particularmente relevante. "E" solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. "L" documento que puede plantear dudas sobre una reivindicación de prioridad o que se cita para determinar la fecha de publicación de otra cita o por una razón especial (como la indicada). "O" documento que se refiere a una divulgación oral, a una utilización, a una exposición o a cualquier otro medio. "P" documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada. | "T" documento ulterior publicado con posterioridad a la fecha de presentación internacional o de prioridad que no pertenece al estado de la técnica pertinente pero que se cita por permitir la comprensión del principio o teoría que constituye la base de la invención. "X" documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. "Y" documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia. "&" documento que forma parte de la misma familia de patentes. | |
| Fecha en que se ha concluido efectivamente la búsqueda internacional | Fecha de expedición del informe de búsqueda internacional | |
| 20 Septiembre 2013 | 10/12/2013 | |
| Nombre y dirección postal de la Administración encargada de la | Funcionario autorizado | |
| búsqueda internacional European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, N° de fax Fax: (+31-70) 340-3016 | Ripaud, Leslie N° de teléfono | |
| Formulario PCT/ISA/210 (segunda hoja) (Julio 2008) | | |

Solicitud internacional Nº

| Recuadr | ro II Observaciones cuando s del punto 2 de la primer | e estime que algunas reivindicaciones no pueden ser objeto de búsqueda (continuación a hoja) |
|----------|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | forme de búsqueda internacional i | no se ha realizado en relación a ciertas reivindicaciones según el Artículo 17.2)a) por los |
| 1. | Las reivindicaciones N^{os} : se refieren a un objeto con respec | to al cual esta Administración no está obligada a proceder a la búsqueda, a saber: |
| 2. 🗆 | Las reivindicaciones N ^{os} : se refieren a elementos de la soli efectuarse una búsqueda provecho | citud internacional que no cumplen con los requisitos establecidos, de tal modo que no pueda osa, concretamente: |
| 3. 🗆 | Las reivindicaciones N ^{os} : son reivindicaciones dependientes | s y no están redactadas de conformidad con los párrafos segundo y tercero de la Regla 6.4.a). |
| Recuadr | ro III Observaciones cuando fa | alta unidad de invención (continuación del punto 3 de la primera hoja) |
| La Admi | inistración encargada de la búsquec | da internacional ha detectado varias invenciones en la presente solicitud internacional, a saber: |
| mi | irar hoja adicional | |
| | | |
| 1. | | ales requeridas han sido satisfechas por el solicitante dentro del plazo, el presente informe de mprende todas las reivindicaciones que pueden ser objeto de búsqueda. |
| 2. | - | nes que pueden ser objeto de búsqueda podrían serlo sin realizar un esfuerzo que justifique tasas no requirió el pago de tasas adicionales. |
| 3. 🗆 | | as tasas adicionales requeridas ha sido satisfecha dentro del plazo por el solicitante, el presente ternacional comprende solamente aquellas reivindicaciones respecto de las cuales han sido te las reivindicaciones N ^{os} : |
| 4. 🛮 | | requeridas ha sido satisfecha por el solicitante dentro de plazo. En consecuencia, el presente ternacional se limita a la invención mencionada en primer término en las reivindicaciones, N ^{os} : |
| 1 | 24(parcial) | |
| Indicaci | ión en cuanto a la protesta | Se acompañó a las tasas adicionales la protesta del solicitante y, en su caso, el pago de una tasa de protesta. Se acompañó a las tasas adicionales la protesta del solicitante, pero la tasa de protesta aplicable no se pagó en el plazo establecido en el requerimiento. El pago de las tasas adicionales no ha sido acompañado de ninguna protesta. |

Solicitud internacional Nº

| | T | I |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Categoría* | Documentos citados, con indicación, si procede, de las partes relevantes | Relevante para las reivindicaciones Nº |
| X | ANONYMOUS: "Taqman array human MicroRNA Cards", INTERNET CITATION, 2010, páginas 1-2, XP002672200, Encontrado en Internet: URL:http://www3.appliedbiosystems.com/cms/ groups/mcb_marketing/documents/generaldocuments/cms_054742.pdf [encontrado en 2012-03-23] todo el documento | 20-23 |
| X | "Cancer MicroRNA qPCR Array with QuantiMir(TM): User manual", 1 Enero 2007 (2007-01-01), XP055080102, Encontrado en Internet: URL:http://www.systembio.com/downloads/Manual_Cancer_miR_qPCR_Array_v2.pdf [encontrado en 2013-09-19] página 5, párrafo D página 6, párrafo step 2 página 10, párrafo D | 20-23 |
| Y | K. LIU ET AL: "Increased Expression of MicroRNA-21 and Its Association with Chemotherapeutic Response in Human Colorectal Cancer", JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol. 39, no. 6, 1 Deciembre 2011 (2011-12-01), páginas 2288-2295, XP055080147, ISSN: 0300-0605, DOI: 10.1177/147323001103900626 página 2289, columna derecha página 2291, columna derecha, párrafo 3rd full página 2291, párrafo puente - página 2292 | 1-17,24 |
| Υ | TORBEN FRÖSTRUP HANSEN ET AL: "The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 8 Marzo 2012 (2012-03-08), página 83, XP021118144, ISSN: 1471-2407, DOI: 10.1186/1471-2407-12-83 resumen | 1-17,24 |
| | -/ | |

Solicitud internacional Nº

| GIUSEPPINA DELLA VITTORIA SCARPATI ET AL: "A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGYBIOLOGYPHYSICS, vol. 83, no. 4, 13 Deciembre 2011 (2011-12-13), páginas 1113-1119, XP055080148, ISSN: 0360-3016, 1001: 10.1016/j.ijrobp.2011.09.030 resumen KEN KUROKAMA ET AL: "Role of miR-19b and its target mRMAs in 5-fluorouracil resistance in colon cancer cells", JOURNAL OF GASTROEMTEROLOGY, SPRINGER-VERLAG, TO, vol. 47, no. 8, 1 Marzo 2012 (2012-03-01), páginas 883-895, XP035100951, ISSN: 1435-5922, D01: 10.1007/S00335-012-0947-6 resumen Rolf Søkilde ET AL: "A new diagnostic platform for prediction of drug response based on a tumor's microRNA profile", 23 Febrero 2009 (2009-02-23), XP055080160, Encontrado en Internet: URL:http://www.exigon.com/ls/Documents/Scientific/15_20b_EDR V1_update_jan09_ HI.pdf [encontrado en 2013-09-19] resumen páginas 2, columna derecha, párrafo 2nd todo todo 1 J V Schou ET AL: "Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment", J Clin Oncol, I Febrero 2011 (2011-02-01), XP055080168, Encontrado en Internet: URL:http://meetinglibrary.asco.org/print/5 71892 [encontrado en 2013-09-19] resumen -/ | (continuación). | DOCUMENTOS CONSIDERADOS RELEVANTES | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| "A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGYPIOLOGYPHYSICS, vol. 83, no. 4, 13 Deciembre 2011 (2011-12-13), páginas 1113-1119, XP65508018A, ISSN: 0360-3016, DOI: 10.1016/j.ijrobp.2011.09.030 resumen KEN KUROKAWA ET AL: "Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells", JOURNAL OF GASTROEMTEROLOGY, SPRINGER-VERLAG, TO, vol. 47, no. 8, 1 Marzo 2012 (2012-03-01), páginas 883-895, XP6035100951, ISSN: 1435-9222, DOI: 10.1007/S00535-012-0547-6 resumen Rolf Sakilde ET AL: "A new diagnostic platform for prediction of drug response based on a tumor's microRNA profile", 23 Febrero 2009 (2009-02-23), XP055080160, Encontrado en Internet: URL:http://www.exigon.com/ls/Documents/Sci entific/15 20b EDR V1 update_jan09_ HI.pdf [encontrado en 2013-09-19] resumen páginas 2, columna derecha, párrafo 2nd todo todo tabla 1B 7 J Schou ET AL: "Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment", J Clin Oncol, 1 Febrero 2011 (2011-02-01), XP055080168, Encontrado en Internet: URL:http://weetinglibrary.asco.org/print/5 71892 [encontrado en 2013-09-19] resumen | Categoría* | Documentos citados, con indicación, si procede, de las partes relevantes | Relevante para las reivindicaciones Nº |
| KEN KUROKAWA ET AL: "Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells", JOURNAL OF GASTROENTEROLOGY, SPRINGER-VERLAG, TO, vol. 47, no. 8, 1 Marzo 2012 (2012-03-01), páginas 883-895, KP035100951, ISSN: 1435-5922, DOI: 10.1007/S00535-012-0547-6 resumen Rolf Søkilde ET AL: "A new diagnostic platform for prediction of drug response based on a tumor's microRNA profile", 23 Febrero 2009 (2009-02-23), XP055080160, Encontrado en Internet: URL:http://www.exiqon.com/ls/Documents/Scientific/15 20b EDR V1 update_jan09_ HI.pdf [encontrado en 2013-09-19] resumen páginas 2, columna derecha, párrafo 2nd todo tabla 1B Y J V Schou ET AL: "Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment", J Clin Oncol, 1 Febrero 2011 (2011-02-01), XP055080168, Encontrado en Internet: URL:http://meetinglibrary.asco.org/print/5 71892 [encontrado en 2013-09-19] resumen | | "A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGYBIOLOGYPHYSICS, vol. 83, no. 4, 13 Deciembre 2011 (2011-12-13), páginas 1113-1119, XP055080148, ISSN: 0360-3016, DOI: 10.1016/j.ijrobp.2011.09.030 | 1-17,24 |
| Rolf Søkilde ET AL: "A new diagnostic platform for prediction of drug response based on a tumor's microRNA profile", 23 Febrero 2009 (2009-02-23), | | its target mRNAs in 5-fluorouracil resistance in colon cancer cells", JOURNAL OF GASTROENTEROLOGY, SPRINGER-VERLAG, TO, vol. 47, no. 8, 1 Marzo 2012 (2012-03-01), páginas 883-895, XP035100951, ISSN: 1435-5922, DOI: 10.1007/S00535-012-0547-6 | 1-17,24 |
| XP055080160, Encontrado en Internet: URL:http://www.exiqon.com/ls/Documents/Sci entific/15_20b_EDR_V1_update_jan09_ HI.pdf [encontrado en 2013-09-19] resumen páginas 2, columna derecha, párrafo 2nd todo tabla 1B J V Schou ET AL: "Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment", J Clin Oncol, 1 Febrero 2011 (2011-02-01), XP055080168, Encontrado en Internet: URL:http://meetinglibrary.asco.org/print/5 71892 [encontrado en 2013-09-19] resumen | Y | Rolf Søkilde ET AL: "A new diagnostic platform for prediction of drug response | 1-24 |
| J V Schou ET AL: "Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment", J Clin Oncol, 1 Febrero 2011 (2011-02-01), XP055080168, Encontrado en Internet: URL:http://meetinglibrary.asco.org/print/5 71892 [encontrado en 2013-09-19] resumen | | XP055080160, Encontrado en Internet: URL:http://www.exiqon.com/ls/Documents/Sci entific/15_20b_EDR_V1_update_jan09_ HI.pdf [encontrado en 2013-09-19] resumen páginas 2, columna derecha, párrafo 2nd todo | |
| | Y | in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment", J Clin Oncol, 1 Febrero 2011 (2011-02-01), XP055080168, Encontrado en Internet: URL:http://meetinglibrary.asco.org/print/571892 [encontrado en 2013-09-19] | 1-24 |
| | | | |

Solicitud internacional Nº

| Categoría* | Documentos citados, con indicación, si procede, de las partes relevantes | Relevante para las reivindicaciones No |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| A | SCHETTER AARON J ET AL: "MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 299, no. 4, 30 Enero 2008 (2008-01-30), páginas 425-436, XP002529936, ISSN: 0098-7484, DOI: 10.1001/JAMA.299.4.425 abstract página 7 - página 8 | 1-24 |
| А | Y DONG ET AL: "MicroRNA dysregulation in colorectal cancer: a clinical perspective", BRITISH JOURNAL OF CANCER, vol. 104, no. 6, 1 March 2011 (2011-03-01), páginas 893-898, XP055080175, ISSN: 0007-0920, DOI: 10.1038/bjc.2011.57 página 895 - páginas 896 | 1-24 |
| A | US 2009/221609 A1 (DEL RIO MARGUERITE [FR] ET AL) 3 Septiembre 2009 (2009-09-03) párrafos [0008], [0134] - [0175] | 1-24 |

| INFORME DE BÚSQUEDA INTERNACIONAL | Solicitud internacional Nº |
|-----------------------------------|----------------------------|
| | PCT/ ES2013/ 070218 |
| | 1 01/ E32013/ 0/0218 |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Información relativa a miembros de familias de patentes

Solicitud internacional N°
PCT/ ES2013/ 070218

| | on relati | va a miembros de fami | mas de p | materites | PC1/ E32013/ 0/02 | LC |
|---------------|-----------|-----------------------|----------------------------|--------------------------------------------------------------|-----------------------------------------------------------------|----|
| US 2009221609 | A1 | | CA EP JP US WO | 2643225 1994177 2009528061 2009221609 2007100859 | A2 26-11-2008 A 06-08-2009 A1 03-09-2009 A2 07-09-2007 | |
| | | | | | AZ 07-09-2007 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

International application No PCT/ES2013/070218

a. classification of subject matter INV. C12Q1/68

C. DOCUMENTS CONSIDERED TO BE RELEVANT

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, FSTA, WPI Data

| Category* | Citation of document, with indication, where appropriate, of the re | elevant passages | Relevant to claim No. |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| X | N Knijn: "Current Issues in the Therapy of Advanced Colorectal (Discovery Medicine, 10 April 2010 (2010-04-10), XPOS Retrieved from the Internet: URL:http://www.discoverymedicine-Knijn/2010/04/10/current-issues rgeted-therapy-of-advanced-colorer/ [retrieved on 2013-09-19] abstract paragraph [introduction] tables 1, 2a | Cancer", 55080024, e.com/Nikki s-in-the-ta | 18,19 |
| لنا ا | ner documents are listed in the continuation of Box C. | X See patent family annex. | |
| "A" docume to be o "E" earlier a filing d "L" docume | nt which may throw doubts on priority claim(s) or which is | "T" later document published after the inter date and not in conflict with the applica- the principle or theory underlying the i "X" document of particular relevance; the c considered novel or cannot be consid- step when the document is taken alon | ation but cited to understand nvention laimed invention cannot be ered to involve an inventive |
| specia "O" docume means | | "Y" document of particular relevance; the c considered to involve an inventive ste combined with one or more other such being obvious to a person skilled in the | o when the document is o documents, such combination |
| "P" docume the pri | ent published prior to the international filing date but later than ority date claimed | "&" document member of the same patent | amily |
| Date of the a | actual completion of the international search | Date of mailing of the international sea | rch report |
| 21 | 0 September 2013 | 10/12/2013 | |
| Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016 | | Authorized officer Ripaud, Leslie | |

| C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT | | | | |
|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|--|--|
| C(Continua | , | I | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | | |
| X | ANONYMOUS: "Taqman array human MicroRNA Cards", INTERNET CITATION, 2010, pages 1-2, XP002672200, Retrieved from the Internet: URL:http://www3.appliedbiosystems.com/cms/ groups/mcb_marketing/documents/generaldocuments/cms_054742.pdf [retrieved on 2012-03-23] the whole document | 20-23 | | |
| X | "Cancer MicroRNA qPCR Array with QuantiMir(TM): User manual", 1 January 2007 (2007-01-01), XP055080102, Retrieved from the Internet: URL:http://www.systembio.com/downloads/Manual_Cancer_miR_qPCR_Array_v2.pdf [retrieved on 2013-09-19] page 5, paragraph D page 6, paragraph b 2 page 10, paragraph D | 20-23 | | |
| Y | K. LIU ET AL: "Increased Expression of MicroRNA-21 and Its Association with Chemotherapeutic Response in Human Colorectal Cancer", JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol. 39, no. 6, 1 December 2011 (2011-12-01), pages 2288-2295, XP055080147, ISSN: 0300-0605, DOI: 10.1177/147323001103900626 page 2289, right-hand column page 2291, right-hand column, paragraph 3rd full page 2291, paragraph bridging - page 2292 | 1-17,24 | | |
| Y | TORBEN FRÖSTRUP HANSEN ET AL: "The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 8 March 2012 (2012-03-08), page 83, XP021118144, ISSN: 1471-2407, DOI: 10.1186/1471-2407-12-83 abstract | 1-17,24 | | |

| C(Continua | tion). DOCUMENTS CONSIDERED TO BE RELEVANT | |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| Υ | GIUSEPPINA DELLA VITTORIA SCARPATI ET AL: "A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGYBIOLOGYPHYSICS, vol. 83, no. 4, 13 December 2011 (2011-12-13), pages 1113-1119, XP055080148, ISSN: 0360-3016, DOI: 10.1016/j.ijrobp.2011.09.030 abstract | 1-17,24 |
| Υ | KEN KUROKAWA ET AL: "Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells", JOURNAL OF GASTROENTEROLOGY, SPRINGER-VERLAG, TO, vol. 47, no. 8, 1 March 2012 (2012-03-01), pages 883-895, XP035100951, ISSN: 1435-5922, DOI: 10.1007/S00535-012-0547-6 abstract | 1-17,24 |
| A | Rolf Søkilde ET AL: "A new diagnostic platform for prediction of drug response based on a tumor's microRNA profile", 23 February 2009 (2009-02-23), XP055080160, Retrieved from the Internet: URL:http://www.exiqon.com/ls/Documents/Scientific/15_20b_EDR_V1_update_jan09_ HI.pdf [retrieved on 2013-09-19] abstract page 2, right-hand column, paragraph 2nd full table 1B | 1-24 |
| A | J V Schou ET AL: "Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment", J Clin Oncol, 1 February 2011 (2011-02-01), XP055080168, Retrieved from the Internet: URL:http://meetinglibrary.asco.org/print/571892 [retrieved on 2013-09-19] abstract | 1-24 |

| 0(0 :: | # DOOLHENTO OONODERER TO BE BELEVIANT | <u> </u> |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| C(Continua | tion). DOCUMENTS CONSIDERED TO BE RELEVANT | T |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | SCHETTER AARON J ET AL: "MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 299, no. 4, 30 January 2008 (2008-01-30), pages 425-436, XP002529936, ISSN: 0098-7484, DOI: 10.1001/JAMA.299.4.425 abstract page 7 - page 8 | 1-24 |
| Α | Y DONG ET AL: "MicroRNA dysregulation in colorectal cancer: a clinical perspective", BRITISH JOURNAL OF CANCER, vol. 104, no. 6, 1 March 2011 (2011-03-01), pages 893-898, XP055080175, ISSN: 0007-0920, DOI: 10.1038/bjc.2011.57 page 895 - page 896 | 1-24 |
| A | US 2009/221609 A1 (DEL RIO MARGUERITE [FR] ET AL) 3 September 2009 (2009-09-03) paragraphs [0008], [0134] - [0175] | 1-24 |

International application No. PCT/ES2013/070218

INTERNATIONAL SEARCH REPORT

| Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet) |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: |
| Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: |
| Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: |
| 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). |
| Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet) |
| This International Searching Authority found multiple inventions in this international application, as follows: |
| see additional sheet |
| As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. |
| 2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees. |
| 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: |
| 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-24(partially) |
| The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. No protest accompanied the payment of additional search fees. |

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-24(partially)

concerns a method of predicting response of a subject suffering from advanced colorectal cancer (CRC) to chemotherapy comprising determining the expression level of a miRNA; concerns also a pharmaceutical composition for treating individuals identified by said method, an antibody for treating individuals identified by said method, a kit comprising an oligonucleotide hybridising to said miRNA, and the use of said kit in said method, wherein said miRNA is SEQ ID N° 1 (miR-107).

2-6. claims: 1-24(partially)

idem invention 1, wherein inventions 2-6 are characterized by the miRNAs of SEQ ID N $^{\circ}$ 2 to 6, respectively. The claims are broken down to the respective inventions according to the SEQ ID N $^{\circ}$ they refer to.

Information on patent family members

| | , | | | | PCT/ES2 | 013/070218 |
|----------------------------------------|----|---------------------|----------------------------|--------------------------------------------------------------|---------------------|--------------------------------------------------------------------|
| Patent document cited in search report | | Publication date | | Patent family member(s) | | Publication date |
| US 2009221609 | A1 | 03-09-2009 | CA EP JP US WO | 2643225 1994177 2009528063 2009221609 2007100859 | 7 A2 L A 9 A1 | 07-09-2007 26-11-2008 06-08-2009 03-09-2009 07-09-2007 |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |